MURRAY, Utah, May 04, 2023 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced results for the three months ended March 31, 2023.
First Quarter 2023 Results:
“Our strong first quarter results demonstrate the team’s focus on execution and our ability to deliver value to stakeholders in a dynamic operating environment,” said Lee Rivas, chief executive officer of R1. “Demand for our services remains robust and we continue to invest in technology to enhance our value proposition for healthcare providers.”
“We are pleased with our first quarter results, which were driven by strong operating discipline and our commitment to customer delivery,” added Jennifer Williams, chief financial officer. “With the momentum generated in the first quarter, we are confident in the balance of 2023. We remain focused on execution to drive sustained long-term growth.”
2023 Outlook
For 2023, R1 continues to expect to generate:
Conference Call and Webcast Details
R1’s management team will host a conference call today at 8:00 a.m. Eastern Time to discuss the Company’s financial results and business outlook. To participate, please dial 888-330-2022 (646-960-0690 outside the U.S. and Canada) using conference code number 5681952. A live webcast and replay of the call will be available at the Investor Relations section of the Company’s website at ir.r1rcm.com.
Non-GAAP Financial Measures
In order to provide a more comprehensive understanding of the information used by R1’s management team in financial and operational decision making, the Company supplements its GAAP consolidated financial statements with certain non-GAAP financial measures, including adjusted EBITDA, non-GAAP cost of services, non-GAAP selling, general and administrative expenses, and net debt. Adjusted EBITDA is defined as GAAP net income before net interest income/expense, income tax provision/benefit, depreciation and amortization expense, share-based compensation expense, CoyCo 2, L.P. (“CoyCo 2”) share-based compensation expense, and certain other items, including business acquisition costs, integration costs, strategic initiatives, and the global business services center expansion project in the Philippines. Non-GAAP cost of services is defined as GAAP cost of services less share-based compensation expense, CoyCo 2 share-based compensation expense, and depreciation and amortization expense attributed to cost of services. Non-GAAP selling, general and administrative expenses is defined as GAAP selling, general and administrative expenses less share-based compensation expense, CoyCo 2 share-based compensation expense, and depreciation and amortization expense attributed to selling, general and administrative expenses. Net debt is defined as debt less cash and cash equivalents, inclusive of restricted cash. Adjusted EBITDA guidance is reconciled to operating income guidance, the most closely comparable available GAAP measure.
Our board of directors and management team use adjusted EBITDA as (i) one of the primary methods for planning and forecasting overall expectations and for evaluating actual results against such expectations and (ii) a performance evaluation metric in determining achievement of certain executive incentive compensation programs, as well as for incentive compensation programs for employees. Non-GAAP cost of services and non-GAAP selling, general and administrative expenses are used to calculate adjusted EBITDA. Net debt is used as a supplemental measure of our liquidity.
Tables 4 through 9 present a reconciliation of GAAP financial measures to non-GAAP financial measures. Non-GAAP measures should be considered in addition to, but not as a substitute for, the information prepared in accordance with GAAP.
Forward-Looking Statements
This press release contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally relate to future events and relationships, plans, future growth, and future performance. These statements are often identified by the use of words such as “anticipate,” “believe,” “contemplate,” “designed,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “designed,” “may,” “outlook,” “plan,” “predict,” “project,” “see,” “seek,” “target,” “would,” and similar expressions or variations or negatives of these words, although not all forward-looking statements contain these identifying words. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the Company’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, assurance, prediction or definitive statement of fact or probability. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks, and changes in circumstances, including but not limited to risk and uncertainties related to: (i) economic downturns and market conditions beyond the Company’s control, including periods of inflation; (ii) the quality of global financial markets; (iii) the Company’s ability to timely and successfully achieve the anticipated benefits and potential synergies of the acquisition of Cloudmed; (iv) the Company’s ability to retain existing customers or acquire new customers; (v) the development of markets for the Company’s revenue cycle management offering; (vi) variability in the lead time of prospective customers; (vii) competition within the market; (viii) breaches or failures of the Company’s information security measures or unauthorized access to a customer’s data; (ix) delayed or unsuccessful implementation of the Company’s technologies or services, or unexpected implementation costs; (x) disruptions in or damages to the Company’s global business services centers and third-party operated data centers; (xi) the volatility of the Company’s stock price; (xii) the Company’s substantial indebtedness; and (xiii) the ongoing impact of the COVID-19 pandemic on the Company’s business, operating results, and financial condition. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the heading “Risk Factors” in the Company’s annual report on Form 10-K for the year ended December 31, 2022, and any other periodic reports that the Company may file with the United States Securities and Exchange Commission. The foregoing list of factors is not exhaustive. All forward-looking statements included herein are expressly qualified in their entirety by these cautionary statements as of the date hereof and involve many risks and uncertainties that could cause the Company’s actual results to differ materially from those expressed or implied in the Company’s forward-looking statements. Subsequent events and developments, including actual results or changes in the Company’s assumptions, may cause the Company’s views to change. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law. You are cautioned not to place undue reliance on such forward-looking statements.
About R1 RCM
R1 is a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers. R1’s proven and scalable operating models seamlessly complement a healthcare organization’s infrastructure, quickly driving sustainable improvements to net patient revenue and cash flows while reducing operating costs and enhancing the patient experience. To learn more, visit: www.r1rcm.com.
Contact:
R1 RCM Inc.
Investor Relations:
Atif Rahim
312-324-5476
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Relations:
Allison+Partners
Amanda Critelli
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Table 1 | ||||||||
| R1 RCM Inc. | ||||||||
| Consolidated Balance Sheets | ||||||||
| (In millions) | ||||||||
| (Unaudited) | ||||||||
| March 31, | December 31, | |||||||
| 2023 | 2022 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 104.2 | $ | 110.1 | ||||
| Accounts receivable, net of $16.0 million and $15.1 million allowance as of March 31, 2023 and December 31, 2022, respectively | 229.4 | 235.2 | ||||||
| Accounts receivable, net of $0.1 million and $0.1 million allowance - related party as of March 31, 2023 and December 31, 2022, respectively | 24.9 | 25.0 | ||||||
| Current portion of contract assets, net | 81.8 | 83.9 | ||||||
| Prepaid expenses and other current assets | 105.2 | 110.3 | ||||||
| Total current assets | 545.5 | 564.5 | ||||||
| Property, equipment and software, net | 173.8 | 164.8 | ||||||
| Operating lease right-of-use assets | 81.0 | 80.5 | ||||||
| Non-current portion of contract assets, net | 37.3 | 32.0 | ||||||
| Non-current portion of deferred contract costs | 28.2 | 26.7 | ||||||
| Intangible assets, net | 1,464.4 | 1,514.5 | ||||||
| Goodwill | 2,648.5 | 2,658.2 | ||||||
| Deferred tax assets | 10.5 | 10.4 | ||||||
| Other assets | 83.4 | 88.2 | ||||||
| Total assets | $ | 5,072.6 | $ | 5,139.8 | ||||
| Liabilities | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 24.6 | $ | 33.4 | ||||
| Current portion of customer liabilities | 45.6 | 57.5 | ||||||
| Current portion of customer liabilities - related party | 9.4 | 7.4 | ||||||
| Accrued compensation and benefits | 84.7 | 109.0 | ||||||
| Current portion of operating lease liabilities | 18.8 | 18.0 | ||||||
| Current portion of long-term debt | 58.3 | 53.9 | ||||||
| Accrued expenses and other current liabilities | 76.7 | 70.6 | ||||||
| Total current liabilities | 318.1 | 349.8 | ||||||
| Non-current portion of customer liabilities | 5.2 | 5.0 | ||||||
| Non-current portion of customer liabilities - related party | 13.2 | 13.7 | ||||||
| Non-current portion of operating lease liabilities | 92.7 | 94.4 | ||||||
| Long-term debt | 1,707.0 | 1,732.6 | ||||||
| Deferred tax liabilities | 192.1 | 200.7 | ||||||
| Other non-current liabilities | 24.9 | 23.1 | ||||||
| Total liabilities | 2,353.2 | 2,419.3 | ||||||
| Stockholders’ equity: | ||||||||
| Common stock | 4.4 | 4.4 | ||||||
| Additional paid-in capital | 3,136.2 | 3,123.2 | ||||||
| Accumulated deficit | (121.6 | ) | (121.9 | ) | ||||
| Accumulated other comprehensive loss | (4.6 | ) | (3.4 | ) | ||||
| Treasury stock | (295.0 | ) | (281.8 | ) | ||||
| Total stockholders’ equity | 2,719.4 | 2,720.5 | ||||||
| Total liabilities and stockholders’ equity | $ | 5,072.6 | $ | 5,139.8 | ||||
| Table 2 | ||||||
| R1 RCM Inc. | ||||||
| Consolidated Statements of Operations (Unaudited) | ||||||
| (In millions, except share and per share data) | ||||||
| Three Months Ended March 31, | ||||||
| 2023 | 2022 | |||||
| Net operating fees | $ | 361.0 | $ | 322.8 | ||
| Incentive fees | 23.6 | 30.2 | ||||
| Modular and other | 161.0 | 32.7 | ||||
| Net services revenue | 545.6 | 385.7 | ||||
| Operating expenses: | ||||||
| Cost of services | 434.7 | 296.5 | ||||
| Selling, general and administrative | 47.0 | 28.9 | ||||
| Other expenses | 30.2 | 17.1 | ||||
| Total operating expenses | 511.9 | 342.5 | ||||
| Income from operations | 33.7 | 43.2 | ||||
| Net interest expense | 30.7 | 4.7 | ||||
| Income before income tax provision | 3.0 | 38.5 | ||||
| Income tax provision | 2.7 | 9.1 | ||||
| Net income | $ | 0.3 | $ | 29.4 | ||
| Net income per common share: | ||||||
| Basic | $ | — | $ | 0.11 | ||
| Diluted | $ | — | $ | 0.09 | ||
| Weighted average shares used in calculating net income per common share: | ||||||
| Basic | 417,346,840 | 278,747,261 | ||||
| Diluted | 452,925,789 | 321,043,371 | ||||
| Table 3 | ||||||||
| R1 RCM Inc. | ||||||||
| Consolidated Statements of Cash Flows (Unaudited) | ||||||||
| (In millions) | ||||||||
| Three Months Ended March 31, | ||||||||
| 2023 | 2022 | |||||||
| Operating activities | ||||||||
| Net income | $ | 0.3 | $ | 29.4 | ||||
| Adjustments to reconcile net income to net cash provided by operations: | ||||||||
| Depreciation and amortization | 66.0 | 18.9 | ||||||
| Amortization of debt issuance costs | 1.4 | 0.3 | ||||||
| Share-based compensation | 10.5 | 10.1 | ||||||
| CoyCo 2 share-based compensation | 1.8 | — | ||||||
| Loss on disposal and right-of-use asset write-downs | — | 2.0 | ||||||
| Provision for credit losses | 1.5 | — | ||||||
| Deferred income taxes | 1.8 | 7.3 | ||||||
| Non-cash lease expense | 2.9 | 3.2 | ||||||
| Other | — | 1.5 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable and related party accounts receivable | 4.7 | 22.1 | ||||||
| Contract assets | (4.0 | ) | — | |||||
| Prepaid expenses and other assets | 8.2 | (20.5 | ) | |||||
| Accounts payable | (10.9 | ) | 3.2 | |||||
| Accrued compensation and benefits | (24.5 | ) | (27.5 | ) | ||||
| Lease liabilities | (4.4 | ) | (2.1 | ) | ||||
| Other liabilities | 9.7 | 1.7 | ||||||
| Customer liabilities and customer liabilities - related party | (10.3 | ) | (18.7 | ) | ||||
| Net cash provided by operating activities | 54.7 | 30.9 | ||||||
| Investing activities | ||||||||
| Purchases of property, equipment, and software | (23.4 | ) | (10.0 | ) | ||||
| Other | (2.2 | ) | — | |||||
| Net cash used in investing activities | (25.6 | ) | (10.0 | ) | ||||
| Financing activities | ||||||||
| Repayment of senior secured debt | (12.4 | ) | (4.4 | ) | ||||
| Repayments on revolver | (10.0 | ) | — | |||||
| Exercise of vested stock options | 0.5 | 0.4 | ||||||
| Purchase of treasury stock | — | (0.6 | ) | |||||
| Shares withheld for taxes | (13.4 | ) | (21.5 | ) | ||||
| Other | (0.1 | ) | (0.1 | ) | ||||
| Net cash used in financing activities | (35.4 | ) | (26.2 | ) | ||||
| Effect of exchange rate changes in cash, cash equivalents and restricted cash | 0.4 | (0.9 | ) | |||||
| Net decrease in cash, cash equivalents and restricted cash | (5.9 | ) | (6.2 | ) | ||||
| Cash, cash equivalents and restricted cash, at beginning of period | 110.1 | 130.1 | ||||||
| Cash, cash equivalents and restricted cash, at end of period | $ | 104.2 | $ | 123.9 | ||||
| Table 4 | ||||||||||||||
| R1 RCM Inc. | ||||||||||||||
| Reconciliation of GAAP Net Income to Non-GAAP Adjusted EBITDA (Unaudited) | ||||||||||||||
| (In millions) | ||||||||||||||
| Three Months Ended March 31, | 2023 vs. 2022 Change | |||||||||||||
| 2023 | 2022 | Amount | % | |||||||||||
| Net income | $ | 0.3 | $ | 29.4 | $ | (29.1 | ) | (99 | ) | % | ||||
| Net interest expense | 30.7 | 4.7 | 26.0 | 553 | % | |||||||||
| Income tax provision | 2.7 | 9.1 | (6.4 | ) | (70 | ) | % | |||||||
| Depreciation and amortization expense | 66.0 | 18.9 | 47.1 | 249 | % | |||||||||
| Share-based compensation expense | 10.5 | 10.1 | 0.4 | 4 | % | |||||||||
| CoyCo 2 share-based compensation expense | 1.8 | — | 1.8 | 100 | % | |||||||||
| Other expenses | 30.2 | 17.1 | 13.1 | 77 | % | |||||||||
| Adjusted EBITDA (non-GAAP) | $ | 142.2 | $ | 89.3 | $ | 52.9 | 59 | % | ||||||
| Table 5 | ||||||
| R1 RCM Inc. | ||||||
| Reconciliation of GAAP Cost of Services to Non-GAAP Cost of Services (Unaudited) | ||||||
| (In millions) | ||||||
| Three Months Ended March 31, | ||||||
| 2023 | 2022 | |||||
| Cost of services | $ | 434.7 | $ | 296.5 | ||
| Less: | ||||||
| Share-based compensation expense | 6.4 | 4.3 | ||||
| CoyCo 2 share-based compensation expense | 0.5 | — | ||||
| Depreciation and amortization expense | 65.6 | 18.6 | ||||
| Non-GAAP cost of services | $ | 362.2 | $ | 273.6 | ||
| Table 6 | ||||||
| R1 RCM Inc. | ||||||
| Reconciliation of GAAP Selling, General and Administrative to Non-GAAP Selling, General and Administrative (Unaudited) | ||||||
| (In millions) | ||||||
| Three Months Ended March 31, | ||||||
| 2023 | 2022 | |||||
| Selling, general and administrative | $ | 47.0 | $ | 28.9 | ||
| Less: | ||||||
| Share-based compensation expense | 4.1 | 5.8 | ||||
| CoyCo 2 share-based compensation expense | 1.3 | — | ||||
| Depreciation and amortization expense | 0.4 | 0.3 | ||||
| Non-GAAP selling, general and administrative | $ | 41.2 | $ | 22.8 | ||
| Table 7 | ||||||
| R1 RCM Inc. | ||||||
| Consolidated Non-GAAP Financial Information (Unaudited) | ||||||
| (In millions) | ||||||
| Three Months Ended March 31, | ||||||
| 2023 | 2022 | |||||
| Net operating fees | $ | 361.0 | $ | 322.8 | ||
| Incentive fees | 23.6 | 30.2 | ||||
| Modular and other | 161.0 | 32.7 | ||||
| Net services revenue | 545.6 | 385.7 | ||||
| Operating expenses: | ||||||
| Cost of services (non-GAAP) | 362.2 | 273.6 | ||||
| Selling, general and administrative (non-GAAP) | 41.2 | 22.8 | ||||
| Sub-total | 403.4 | 296.4 | ||||
| Adjusted EBITDA | $ | 142.2 | $ | 89.3 | ||
| Table 8 | |
| R1 RCM Inc. | |
| Reconciliation of GAAP Operating Income Guidance to Non-GAAP Adjusted EBITDA Guidance (Unaudited) | |
| (In millions) | |
| 2023 | |
| GAAP Operating Income Guidance | $115-140 |
| Plus: | |
| Depreciation and amortization expense | $260-280 |
| Share-based compensation expense | $75-85 |
| CoyCo 2 share-based compensation expense | $10-15 |
| Strategic initiatives, severance and other costs | $110-135 |
| Adjusted EBITDA Guidance | $595-630 |
| Table 9 | ||||||
| R1 RCM Inc. | ||||||
| Reconciliation of Total Debt to Net Debt (Unaudited) | ||||||
| (In millions) | ||||||
| March 31, | December 31, | |||||
| 2023 | 2022 | |||||
| Senior Revolver | $ | 90.0 | $ | 100.0 | ||
| Term A Loans | 1,200.3 | 1,211.4 | ||||
| Term B Loan | 497.5 | 498.7 | ||||
| Total debt | 1,787.8 | 1,810.1 | ||||
| Less: | ||||||
| Cash and cash equivalents | 104.2 | 110.1 | ||||
| Net Debt | $ | 1,683.6 | $ | 1,700.0 | ||
| Last Trade: | US$14.31 |
| Daily Volume: | 0 |
| Market Cap: | US$6.040B |
November 05, 2024 August 07, 2024 August 01, 2024 June 17, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
